Related Experiment Video

Updated: Jun 21, 2026

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis
06:46

3D Imaging of the Liver Extracellular Matrix in a Mouse Model of Non-Alcoholic Steatohepatitis

Published on: February 25, 2022

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C

Pierre-Yves Bochud1, Tao Cai, Kathrin Overbeck

  • 1Department of Internal Medicine, Infectious Diseases Service, CHUV, Lausanne, Switzerland.

Journal of Hepatology
|August 12, 2009
PubMed

Insights

Hepatitis C virus (HCV) genotype 3 significantly accelerates liver fibrosis progression in patients. Male sex, older age at infection, and higher histological activity also predict faster fibrosis, impacting patient management strategies.

Area of Science:

  • Hepatology
  • Virology
  • Medical Research

Background:

  • Chronic hepatitis C (HCV) progression is multifactorial, with HCV genotypes' role in liver fibrosis evolution debated.
  • Identifying independent predictors of fibrosis progression is crucial for effective patient management.

Purpose of the Study:

  • To assess independent predictors of liver fibrosis progression in patients with chronic hepatitis C.
  • To investigate the specific contribution of different HCV genotypes to fibrosis evolution.

Main Methods:

  • Analysis of 1189 patients from the Swiss Hepatitis C Cohort database with pre-antiviral treatment liver biopsies.
  • Calculation of stage-constant fibrosis progression rate (Metavir score/duration of infection).
  • Utilized a Markov model for stage-specific progression rates and regression models for risk factor assessment.

Main Results:

  • Male sex, older age at infection, and higher histological activity were independent predictors of accelerated fibrosis.
  • HCV genotype 3 was significantly associated with faster stage-constant and stage-specific fibrosis progression rates compared to other genotypes.
  • Slower fibrosis progression was noted in patients infected via blood transfusion or needle stick compared to intravenous drug use.

Conclusions:

  • HCV genotype 3 is a significant independent predictor of accelerated liver fibrosis.
  • These findings highlight the importance of considering HCV genotype in the clinical management of patients.
  • Further research may refine treatment strategies based on genotype-specific fibrosis progression.
Abstract

More Related Videos

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish09:27

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Published on: April 1, 2021

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...